Joseph J. Ferra Jr. - 24 Jun 2021 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
Chief Financial Officer
Signature
/s/ Shawn Leland, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
24 Jun 2021
Net transactions value
$0
Form type
4
Filing time
28 Jun 2021, 18:23:04 UTC
Next filing
16 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Stock Option (Right to Buy) Award $0 +249,104 $0.000000 249,104 24 Jun 2021 Common Stock 249,104 $16.00 Direct F1
transaction ELEV Restricted Stock Unit (RSU) Award $0 +200,995 $0.000000 200,995 24 Jun 2021 Common Stock 200,995 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the total shares will vest on June 16, 2022, and the remainder will vest as to 1/48 of the total award in monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2 Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.
F3 25% of the RSUs will vest on June 16, 2022, and the remainder will vest in quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.